Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T Therapy

▴ Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T Therapy
Tessa announced, EMA has granted PRiority MEdicines designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma

Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumours, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).

PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. Through this program, EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency.

"We are very pleased that EMA has acknowledged the potential Tessa's CD30 CAR-T therapy holds for patients with Hodgkin Lymphoma" said Jeffrey H. Buchalter, President and CEO of Tessa Therapeutics. "Having received RMAT designation from FDA during 2020, we now hope to work closely with regulatory agencies in both the United States and Europe to expedite clinical development and the registration path for this therapy."

The PRIME designation was granted by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center. These studies showed complete disappearance of tumour in ~60% of patients at the highest dose level with none of the serious toxicities that can be associated with several other CAR-T therapies. These results were published in Journal of Clinical Oncology (Ramos et al., 2020). Based on these data, Tessa plans to commence a multi-center pivotal study in the United States during 2021.

Europe accounts for approximately a quarter of the world's Hodgkin Lymphoma incidence. Tessa's pivotal trial will be recruiting patients from more than 20 cancer centers across the US and Europe including sites in Italy, Spain and Sweden. "CD30 CAR-Ts demonstrated excellent safety and efficacy data in heavily pre-treated R/R cHL patients. We look forward to collaborating with Tessa to further validate these impressive results in the pivotal trial." said Dr Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Italy.

Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics said "CD30 CAR-T therapy, with its promising efficacy and very limited toxicity, can meaningfully address current gaps that exist in the treatment of R/R cHL. We also are exploring the potential of this therapy in CD30 positive subtypes of Non-Hodgkin Lymphoma (NHL)." Tessa's Phase 1 clinical study for patients with relapsed / refractory CD30 positive NHL is open for enrollment in the United States.

Tags : #TessaTherapeutics #LatestNewsonTessaTherapeutics #LatestPharmaNews19thJan #LatestNewsonCancerTreatment #EuropeanMedicinesAgency #USFDA

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Behavioral Changes Towards Innovation in Technology is the Need of the Hour, says Bitopan Sarma Baruah, Head IT and Business Process, Excelcare HospitalsMarch 08, 2021
6 Top Women Entrepreneurs and CXOs are Transforming Healthcare for the BetterMarch 06, 2021
Top 4 reasons to visit a dentist today March 06, 2021
“Reframe your thoughts to prevent Dissociative Identity Disorder (DID)” by Dr.Sheereen K Bajpai, Expert Psychologist & Counselor from Indian Institute of Science Education and ResearchMarch 06, 2021
Digitalization Should Enable Clinicians to Focus on The Human Touch, says Dr. George Fernandes, CEO, Viveka HospitalsMarch 05, 2021
March 5 th 2021- Dissociative Identity Disorder(DID) Awareness DayMarch 04, 2021
Are You Struggling with “Maskne”? Find the Top 5 Solutions to deal with it. March 03, 2021
Exercise could well mimic the effects of Polypill , also it's cheaper and without side effectsMarch 03, 2021
Sorrento receives USFDA clearance to start a clinical trial of Anti-CD47 antibodyMarch 03, 2021
Regular breast checks by trained health workers linked to fewer breast cancer deaths in IndiaMarch 03, 2021
Treat Doctors as Friends and Have an Open Chat with Them says Dr. Shailaja Sabnis, Consultant Physician and Rheumatologist March 03, 2021
PM Jan Aushadhi Kendra inaugurated at District Hospital, KargilMarch 02, 2021
Maharashtra records 6,397 new cases of coronavirus todayMarch 02, 2021
One in four people will have hearing problems by 2050: WHOMarch 02, 2021
6 states show surge in Covid-19 cases, India's total active cases reach 1,68,627March 02, 2021
hday for longer life ; American Heart AssociationMarch 02, 2021
Is your baby cranky due to skin complaints? Here are some quick solutions that can help you.March 02, 2021
Women Have the Right to Say “No”, says Dr. Vaishali Joshi, Senior Obstetrician & Gynaecologist, Kokilaben Ambani Hospital, MumbaiMarch 02, 2021
How to Control STDs, explains, Dr. Nikul Patel, Founder and Chief Ayurveda Consultant of Atharva Ayurveda Clinic and Panchakarma Center March 02, 2021
Registration for next phase of COVID19 Vaccination on Co-WIN2.0 portal will open at 9:00 am on 1st MarchMarch 01, 2021